Soft Tissue Repair Market by Product (Mesh/Tissue patch, Allograft, Xenograft, Suture Anchor, Interference Screws, Laparoscopic Instruments) by Application (Hernia, Dural, Orthopedic, Skin, Dental, Vaginal, Breast augmentation) - Global Forecast to 2019
https://www.marketsandmarkets.com/Market-Reports/soft-tissue-repair-devices-market-216009453.html
The global soft tissue repair market is estimated to grow at a CAGR of 7.5% from 2014 to 2019 to reach $14.7 billion in 2019. The increasing incidence of soft tissue injuries among the active aging population, increasing participation in sports, increasing obesity rate, and increasing healthcare expenditure & lack of substitutes for soft tissue repair surgery are the major factors driving market growth.
The soft tissue repair market is witnessing a gradual shift towards biological meshes from conventional synthetic meshes for soft tissue repair. Such products offer enhanced biocompatibility, strength, and improved aesthetics. However, the high costs of surgical procedures, and the lack of reimbursement are some major factors that could hinder the growth of this market to a certain extent.
The market studied in this report is mainly segmented by products and applications. Based on products, the market is segmented into tissue patch/mesh, soft tissue fixation devices, and laparoscopic instruments. On the basis of application, the market is segmented into hernia repair, dural repair, vaginal sling procedure, skin repair, orthopedic and dental repair, and breast reconstruction repair.
The global market is dominated by North America, followed by Europe. The Asia-Pacific market is expected to witness the highest growth due to the increasing demand for tissue regeneration & orthopedic soft tissue repair procedures (caused by the huge aging population and the rising number of patients with soft tissue injuries). North America and Europe are expected to grow at a sluggish rate since these are relatively saturated markets.
Prominent players in this market are LifeCell Corporation (U.S.), Organogenesis (U.S.), C.R. Bard, Inc. (U.S.), Johnson & Johnson (U.S.), Covidien plc (Ireland), Arthrex, Inc. (U.S.), Smith & Nephew plc (U.K.), Integra Lifesciences Corporation (U.S.), Wright Medical Technology (U.S.), and Stryker Corporation (U.S.).